Gilder Gagnon Howe & Co. LLC increased its position in shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) by 27.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,307,870 shares of the specialty pharmaceutical company’s stock after buying an additional 927,625 shares during the period. Flexion Therapeutics comprises about 1.3% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 21st largest position. Gilder Gagnon Howe & Co. LLC owned about 19.97% of Flexion Therapeutics worth $64,467,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Flexion Therapeutics during the first quarter worth about $1,145,000. Bogle Investment Management L P DE acquired a new position in shares of Flexion Therapeutics during the first quarter valued at $688,000. Sabby Management LLC acquired a new position in shares of Flexion Therapeutics during the first quarter valued at $426,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Flexion Therapeutics during the first quarter valued at $337,000. Finally, Amici Capital LLC acquired a new position in shares of Flexion Therapeutics during the first quarter valued at $184,000. 68.32% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) traded down 0.88% during mid-day trading on Wednesday, hitting $20.32. The company had a trading volume of 78,038 shares. Flexion Therapeutics Inc. has a 12 month low of $7.56 and a 12 month high of $21.71. The firm has a 50-day moving average price of $18.09 and a 200 day moving average price of $15.21. The firm’s market capitalization is $559.23 million.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.04. On average, equities research analysts forecast that Flexion Therapeutics Inc. will post ($2.69) earnings per share for the current fiscal year.

Several research analysts have recently weighed in on FLXN shares. BMO Capital Markets started coverage on Flexion Therapeutics in a research note on Tuesday, June 28th. They set an “outperform” rating and a $35.00 target price for the company. Janney Montgomery Scott reaffirmed a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a research note on Friday, July 1st. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Finally, Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.31.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.